WO2008011168A3 - Glycosylated peptide antagonists of the bradykinin b1 receptor - Google Patents
Glycosylated peptide antagonists of the bradykinin b1 receptor Download PDFInfo
- Publication number
- WO2008011168A3 WO2008011168A3 PCT/US2007/016489 US2007016489W WO2008011168A3 WO 2008011168 A3 WO2008011168 A3 WO 2008011168A3 US 2007016489 W US2007016489 W US 2007016489W WO 2008011168 A3 WO2008011168 A3 WO 2008011168A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bradykinin
- receptor
- peptide antagonists
- glycosylated peptide
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
A compositions of matter and pharmaceutical compositions are disclosed, which in various embodiments, comprise biologically active glycosylated peptides that can be used therapeutically or prophylactically against diseases or conditions linked to bradykinin B1 receptor as the causative agent. A method of treating, preventing, or ameliorating a disease or condition associated with B1 activity is also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83246406P | 2006-07-21 | 2006-07-21 | |
US60/832,464 | 2006-07-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008011168A2 WO2008011168A2 (en) | 2008-01-24 |
WO2008011168A3 true WO2008011168A3 (en) | 2008-06-05 |
Family
ID=38957413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/016489 WO2008011168A2 (en) | 2006-07-21 | 2007-07-20 | Glycosylated peptide antagonists of the bradykinin b1 receptor |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008011168A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113848686B (en) * | 2021-09-26 | 2023-10-27 | 江西达诚新材料有限公司 | Negative photoresist developer and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988002756A2 (en) * | 1986-10-13 | 1988-04-21 | Sandoz Ag | Peptide derivatives |
EP0472220A1 (en) * | 1990-08-24 | 1992-02-26 | Syntex (U.S.A.) Inc. | Bradykinin antagonists |
-
2007
- 2007-07-20 WO PCT/US2007/016489 patent/WO2008011168A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988002756A2 (en) * | 1986-10-13 | 1988-04-21 | Sandoz Ag | Peptide derivatives |
EP0472220A1 (en) * | 1990-08-24 | 1992-02-26 | Syntex (U.S.A.) Inc. | Bradykinin antagonists |
Non-Patent Citations (3)
Title |
---|
C HO ET AL: "Comparison of the immunogenicity of wasp venom peptides with ot without carbohydrate moieties", TOXICON, vol. 36, no. 1, 1998, US ELMSFORD, NY, pages 217 - 221, XP005310749 * |
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, PART C: PHARMACOLOGY, TOXICOLOGY & ENDOCRINOLOGY, 105C(2), 189-96 CODEN: CBPCEE; ISSN: 0742-8413, 1993 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1993, PIEK, T. ET AL: "Presynaptic block of transmission in the insect CNS by mono- and digalactosyl analogs of Vespulakinin 1, a wasp (Paravespula maculifrons) venom neurotoxin", XP002471227, retrieved from STN Database accession no. 119:197529 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008011168A2 (en) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006119958A3 (en) | Use of flibanserin in the treatment of chronic pain | |
WO2007002597A3 (en) | Modified-release formulations of a bupropion salt | |
EP2455462A3 (en) | Lipase variants for pharmaceutical use | |
WO2006034373A8 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
WO2007122580A3 (en) | Compositions of phenylephrine useful for treatment of respiratory illness | |
WO2009009562A3 (en) | Glp-1-fc fusion protein formulation | |
NZ617196A (en) | Activin-actrii antagonists and uses for increasing red blood cell levels | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
WO2007073486A3 (en) | Methods and compositions for delivering active agents with enhanced pharmacological properties | |
IL222880A (en) | Peptides and uses thereof in the treatment and diagnosis of diseases and pharmaceutical compositions comprising the same | |
NZ623123A (en) | A process for concentration of a polypeptide | |
WO2005089803A3 (en) | Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs | |
WO2006100679A3 (en) | Recombinant antibodies against human type ii transglutaminase and uses thereof | |
WO2007007095A3 (en) | Pharmaceutical compositions comprising a tgf-beta superfamily member | |
WO2005042027A3 (en) | Antagonists of the bradykinin b1 receptor | |
WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
PL1969003T3 (en) | Uses of a NEUROTROPHIC FACTOR PROTEIN | |
NZ601592A (en) | Recombinant elastase proteins and methods of manufacturing and use thereof | |
WO2008051496A3 (en) | Use of il-1 antagonists to treat gout and pseudogout | |
EP2510941A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
UA94213C2 (en) | Use of monovalent antibody polypeptide that inhibits cd40 or cd40l activity in the manufacture of a medicament for treating or preventing autoimmune disease | |
AU2003229284A1 (en) | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | |
WO2008062475A3 (en) | Pharmaceutical compositions of ursodiol | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07810665 Country of ref document: EP Kind code of ref document: A2 |